GE, Agfa sign CR OEM agreement
Multimodality vendor GE Medical Systems and Agfa-Gevaert have joined forces in an alliance for sales of computed radiography systems, the companies announced this month. The three-year agreement stipulates that Waukesha, WI-based GE will market, sell,
Multimodality vendor GE Medical Systems and Agfa-Gevaert have joined forces in an alliance for sales of computed radiography systems, the companies announced this month. The three-year agreement stipulates that Waukesha, WI-based GE will market, sell, and service Agfa Diagnostic Center (ADC) Compact and Solo CR systems under the GE label worldwide. Both systems feature Agfas Musica image processing software.
With access to GEs large sales force and widespread installed base of x-ray systems, the deal boosts Agfas reach into markets around the world and gives it an opportunity to expand its CR business, according to the Mortsel, Belgium-based company.
GE moves closer to its goal of providing its customers with tools to transition into a completely digital environment. Agfa replaces Fuji Medical Systems USA as GEs CR supplier. Fuji had signed a similar deal with GE in 1995 (SCAN 8/30/95). At the time, the agreement represented Fujis first OEM deal for its CR readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
